Short Term Estimates And Forecasts For Cardiff Oncology Inc (CRDF)

Cardiff Oncology Inc (NASDAQ:CRDF) has a beta value of 1.56 and has seen 0.45 million shares traded in the recent trading session. The company, currently valued at $249.14M, closed the recent trade at $3.74 per share which meant it gained $0.23 on the day or 6.70% during that session. The CRDF stock price is -50.8% off its 52-week high price of $5.64 and 46.26% above the 52-week low of $2.01. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.96 million shares traded. The 3-month trading volume is 1.14 million shares.

The consensus among analysts is that Cardiff Oncology Inc (CRDF) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.

Cardiff Oncology Inc (NASDAQ:CRDF) trade information

Over the past 30 days, the shares of Cardiff Oncology Inc (NASDAQ:CRDF) have changed 39.74%. Short interest in the company has seen 17.52 million shares shorted with days to cover at 18.4.

Cardiff Oncology Inc (CRDF) estimates and forecasts

The company’s shares have gained 43.49% over the past 6 months.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 19.36% over the past 5 years. Earnings growth for 2025 is a modest 13.83% while over the next 5 years, the company’s earnings are expected to decrease by -8.81%.

CRDF Dividends

Cardiff Oncology Inc is expected to release its next earnings report on 2025-May-07 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Cardiff Oncology Inc (NASDAQ:CRDF)’s Major holders

Insiders own 5.64% of the company shares, while shares held by institutions stand at 45.30% with a share float percentage of 48.01%. Investors are also buoyed by the number of investors in a company, with Cardiff Oncology Inc having a total of 144.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 2.63 million shares worth more than $5.84 million. As of 2024-06-30, BLACKROCK INC. held 5.8637% of shares outstanding.

The other major institutional holder is VANGUARD GROUP INC, with the holding of over 2.14 million shares as of 2024-06-30. The firm’s total holdings are worth over $4.74 million and represent 4.766% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are iShares Trust-iShares Russell 2000 ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . As of Mar 31, 2025 , the former fund manager holds about 2.29% shares in the company for having 1.52 shares of worth $5.79 million while later fund manager owns 1.52 shares of worth $5.79 million as of Mar 31, 2025 , which makes it owner of about 2.29% of company’s outstanding stock.

Marketing Sentinel
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.